A detailed history of Jeremy Grantham (Grantham, Mayo, Van Otterloo & Co. LLC) transactions in Incyte Corp stock. As of the latest transaction made, Grantham, Mayo, Van Otterloo & Co. LLC holds 581,059 shares of INCY stock, worth $40 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
581,059
Previous 585,712 0.79%
Holding current value
$40 Million
Previous $35.5 Million 8.17%
% of portfolio
0.12%
Previous 0.12%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$57.33 - $68.61 $266,756 - $319,242
-4,653 Reduced 0.79%
581,059 $38.4 Million
Q2 2024

Aug 13, 2024

BUY
$51.18 - $63.75 $3.12 Million - $3.88 Million
60,865 Added 11.6%
585,712 $35.5 Million
Q1 2024

May 14, 2024

SELL
$56.55 - $66.59 $864,819 - $1.02 Million
-15,293 Reduced 2.83%
524,847 $29.9 Million
Q4 2023

Feb 13, 2024

BUY
$52.16 - $64.19 $1.76 Million - $2.17 Million
33,828 Added 6.68%
540,140 $33.9 Million
Q3 2023

Nov 13, 2023

BUY
$57.77 - $65.93 $4.95 Million - $5.65 Million
85,702 Added 20.38%
506,312 $29.2 Million
Q2 2023

Aug 14, 2023

SELL
$60.95 - $75.51 $480,895 - $595,773
-7,890 Reduced 1.84%
420,610 $26.2 Million
Q1 2023

May 12, 2023

SELL
$70.23 - $86.01 $105,345 - $129,015
-1,500 Reduced 0.35%
428,500 $31 Million
Q4 2022

Feb 13, 2023

BUY
$67.18 - $84.11 $3.8 Million - $4.75 Million
56,500 Added 15.13%
430,000 $34.5 Million
Q3 2022

Nov 10, 2022

SELL
$66.18 - $82.86 $701,508 - $878,316
-10,600 Reduced 2.76%
373,500 $24.9 Million
Q2 2022

Aug 12, 2022

BUY
$66.18 - $83.18 $99,270 - $124,770
1,500 Added 0.39%
384,100 $29.2 Million
Q1 2022

May 13, 2022

BUY
$66.02 - $79.71 $4.13 Million - $4.99 Million
62,600 Added 19.56%
382,600 $30.4 Million
Q4 2021

Feb 11, 2022

BUY
$63.34 - $74.11 $14 Million - $16.4 Million
221,300 Added 224.21%
320,000 $23.5 Million
Q3 2021

Nov 12, 2021

BUY
$68.67 - $84.02 $6.78 Million - $8.29 Million
98,700 New
98,700 $6.79 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.3B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track Jeremy Grantham's Portfolio

Track Jeremy Grantham Portfolio

Follow Jeremy Grantham (Grantham, Mayo, Van Otterloo & Co. LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.